Clinical Data to send depression drug to FDA - Boston Business Journal:

ogarawo.wordpress.com
Company officials said study results suggestf that vilazodone wasgenerally well-tolerated, and the efficacuy and safety data were consistent with the findingzs from the previous Phase III Company officials say that unlike many anti-depressants, the studyy found that the effects of vilazodone on sexual functioj were comparable to placebo. Clinical Data officialzs also say the studg showed significant improvement in the symptoms of anxiety associatedwith MDD. The Phaser III trial had also sought to studt whether there is a certai n biomarker that identifies which patienta would benefit fromthe drug.
Company officials say they were not successfupl in this part of the but will continue to try to identify ways to target the drug towards those patients who wouldrespond best.